988. Effectiveness of Seasonal Influenza Vaccines Against Influenza A(H3N2) Illness Among Children Aged <18 Years, US Flu VE Network, 2010-2018
Session: Poster Abstract Session: Adult and Pediatric Influenza Vaccine
Friday, October 5, 2018
Room: S Poster Hall
Posters
  • 988_H3N2_VE_Children_2010-18_poster.pdf (733.9 kB)
  • Background: Interim estimates of 2017-18 influenza vaccine effectiveness (VE) against influenza A(H3N2)-related illness in the United States indicated better protection among young children than among older children and adolescents. We examined VE against influenza A(H3N2) illness during five A(H3N2)-predominant seasons from 2010-11 through 2016-17 to investigate differences between VE among younger versus older children.

    Methods: We analyzed data from 11,736 outpatients aged <18 years with medically attended acute respiratory illnesses enrolled at U.S. Flu VE Network study sites during five influenza A(H3N2)-predominant seasons. Respiratory specimens from all enrollees were tested for influenza viruses using reverse transcription PCR. Children with documented receipt of the recommended number of doses of current season inactivated influenza vaccine at least 14 days before illness onset were considered fully vaccinated; partially vaccinated children and those who received live attenuated influenza vaccine were excluded. Vaccine effectiveness was estimated as 100 x (1 – adjusted odds ratio) from multivariable logistic regression adjusting for study site, age, sex, presence of high-risk medical conditions and days from illness onset to enrollment comparing odds of vaccination among A(H3N2)-positive cases versus influenza-negative controls.

    Results: A total of 1854 influenza A(H3N2) cases and 9,882 influenza-negative controls were included; 494 (28%) influenza A(H3N2) cases and 3637 (41%) controls were fully vaccinated before illness onset. VE ranged from 26% (95% confidence interval [CI], -17% to 53%) to 60% (38%-75%) among children aged 6 months-4 years and from 9% (-16% to 29%) to 66% (37%-82%) among 5-17 year olds (Figure). During 2012-13 and 2014-15, A(H3N2) VE estimates were significantly higher among younger compared to older children (p<0.05); in other seasons before 2017-18, A(H3N2) VE estimates were similar among younger and older children.

    Conclusion: Higher VE against A(H3N2) viruses in younger versus older children in some seasons suggests immunologic differences in response to vaccine components. Overall, inactivated influenza vaccine provided moderate protection against A(H3N2)-related illness among children.

    Brendan L. Flannery, PhD1, Jessie Chung, MPH1, Michael L. Jackson, PhD, MPH2, Lisa A. Jackson, MD, MPH, FIDSA2, Arnold S. Monto, MD, FIDSA3, Emily T. Martin, MPH, PhD3, Edward Belongia, MD4, Huong McLean, PhD, MPH4, Richard K. Zimmerman, MD MPH, FIDSA5, Mary Patricia Nowalk, PhD RD6, Manjusha Gaglani, MBBS7, Marie R. Griffin, MD, MPH8, H. Keipp Talbot, MD, MPH9, John J. Treanor, MD10, Sarah Spencer, PhD11 and Alicia M. Fry, MD, MPH1, (1)Influenza Division, Centers for Disease Control and Prevention, Atlanta, GA, (2)Kaiser Permanente Washington Health Research Institute, Seattle, WA, (3)Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, MI, (4)Marshfield Clinic Research Institute, Marshfield, WI, (5)University of Pittsburgh, Pittsburgh, PA, (6)Family Medicine, University of Pittsburgh, Pittsburgh, PA, (7)Pediatrics; Pediatric Infectious Diseases, Baylor Scott & White Health, Texas A&M University Health Science Center College of Medicine, Temple, TX, (8)Vanderbilt University Medical Center, Nashville, TN, (9)Infectious Diseases, Vanderbilt University Medical Center, Nashville, TN, (10)Medicine, University of Rochester Medical Center School of Medicine and Dentistry, Rochester, NY, (11)Centers for Disease Control and Prevention, Atlanta, GA

    Disclosures:

    B. L. Flannery, None

    J. Chung, None

    M. L. Jackson, Sanofi Pasteur: Grant Investigator , Research support .

    L. A. Jackson, Novartis: Grant Investigator , Research support .

    A. S. Monto, None

    E. T. Martin, None

    E. Belongia, None

    H. McLean, None

    R. K. Zimmerman, Sanofi Pasteur: Grant Investigator , Research support . Pfizer: Grant Investigator , Research support . Merck: Grant Investigator , Research support .

    M. P. Nowalk, Merck: Grant Investigator , Research support . Pfizer: Grant Investigator , Research support .

    M. Gaglani, None

    M. R. Griffin, MedImmune: Grant Investigator , Research support .

    H. K. Talbot, Sanofi Pasteur: Investigator , Research grant . Gilead: Investigator , Research grant . MedImmune: Investigator , Research grant . Vaxinnate: Safety Board , none . Seqirus: Safety Board , none .

    J. J. Treanor, Novartis: Board Member and Consultant , Consulting fee .

    S. Spencer, None

    A. M. Fry, None

    Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 3rd with the exception of research findings presented at the IDWeek press conferences.